CN114903924A - Composition containing myrobalan fruit extract, preparation method, application and hair care product - Google Patents
Composition containing myrobalan fruit extract, preparation method, application and hair care product Download PDFInfo
- Publication number
- CN114903924A CN114903924A CN202110185513.4A CN202110185513A CN114903924A CN 114903924 A CN114903924 A CN 114903924A CN 202110185513 A CN202110185513 A CN 202110185513A CN 114903924 A CN114903924 A CN 114903924A
- Authority
- CN
- China
- Prior art keywords
- fruit extract
- myrobalan
- myrobalan fruit
- hair
- caffeine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000011517 Terminalia chebula Nutrition 0.000 title claims abstract description 96
- 235000015489 Emblica officinalis Nutrition 0.000 title claims abstract description 95
- 235000013399 edible fruits Nutrition 0.000 title claims abstract description 92
- 239000000203 mixture Substances 0.000 title claims abstract description 68
- 210000004209 hair Anatomy 0.000 title claims abstract description 25
- 238000002360 preparation method Methods 0.000 title claims abstract description 9
- 244000277583 Terminalia catappa Species 0.000 title claims abstract 33
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 claims abstract description 48
- 201000004384 Alopecia Diseases 0.000 claims abstract description 27
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 claims abstract description 24
- 229960001948 caffeine Drugs 0.000 claims abstract description 24
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 claims abstract description 24
- YTKGAYFHUZTLCI-UHFFFAOYSA-N 3-hydroxy-2-iminopyrimidin-4-amine Chemical compound NC1=CC=NC(=N)N1O YTKGAYFHUZTLCI-UHFFFAOYSA-N 0.000 claims abstract description 21
- 230000014509 gene expression Effects 0.000 claims abstract description 12
- 230000003078 antioxidant effect Effects 0.000 claims abstract description 10
- 230000003676 hair loss Effects 0.000 claims abstract description 9
- 208000024963 hair loss Diseases 0.000 claims abstract description 8
- 230000028327 secretion Effects 0.000 claims abstract description 8
- SKQIRRPTHXKMFU-UHFFFAOYSA-N N1(CCCC1)C1=[N+](C(=CC(=N1)N)N)[O-] Chemical compound N1(CCCC1)C1=[N+](C(=CC(=N1)N)N)[O-] SKQIRRPTHXKMFU-UHFFFAOYSA-N 0.000 claims abstract description 7
- -1 diaminopyrimidine oxide compound Chemical class 0.000 claims abstract description 7
- 101000574445 Homo sapiens Alkaline phosphatase, tissue-nonspecific isozyme Proteins 0.000 claims abstract description 5
- 101000762366 Homo sapiens Bone morphogenetic protein 2 Proteins 0.000 claims abstract description 5
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 claims abstract description 5
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims abstract description 5
- 108700007229 noggin Proteins 0.000 claims abstract description 5
- 102100025683 Alkaline phosphatase, tissue-nonspecific isozyme Human genes 0.000 claims abstract description 4
- 102100024506 Bone morphogenetic protein 2 Human genes 0.000 claims abstract description 4
- 102100032912 CD44 antigen Human genes 0.000 claims abstract description 4
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 claims abstract description 4
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims abstract description 4
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims abstract description 4
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims abstract description 4
- 102000045246 noggin Human genes 0.000 claims abstract description 4
- 241000001522 Terminalia chebula Species 0.000 claims description 70
- 239000000047 product Substances 0.000 claims description 17
- 210000000642 hair follicle dermal papilla cell Anatomy 0.000 claims description 15
- 238000000605 extraction Methods 0.000 claims description 13
- 230000003779 hair growth Effects 0.000 claims description 13
- 231100000360 alopecia Toxicity 0.000 claims description 12
- 108090000623 proteins and genes Proteins 0.000 claims description 12
- 239000003963 antioxidant agent Substances 0.000 claims description 8
- 239000000706 filtrate Substances 0.000 claims description 6
- 238000001914 filtration Methods 0.000 claims description 6
- 239000002904 solvent Substances 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 5
- 239000008367 deionised water Substances 0.000 claims description 4
- 229910021641 deionized water Inorganic materials 0.000 claims description 4
- 238000001035 drying Methods 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical group O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- 238000004108 freeze drying Methods 0.000 claims description 3
- 239000000463 material Substances 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 229940113178 5 Alpha reductase inhibitor Drugs 0.000 claims description 2
- 239000002677 5-alpha reductase inhibitor Substances 0.000 claims description 2
- RSMJUJQJXRIIQS-UHFFFAOYSA-N NC1=CC(=NC=[N+]1[O-])N Chemical class NC1=CC(=NC=[N+]1[O-])N RSMJUJQJXRIIQS-UHFFFAOYSA-N 0.000 claims description 2
- 241000510764 Villosa Species 0.000 claims description 2
- 238000005119 centrifugation Methods 0.000 claims description 2
- 238000011161 development Methods 0.000 claims description 2
- 230000003834 intracellular effect Effects 0.000 claims description 2
- 239000002085 irritant Substances 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 238000003756 stirring Methods 0.000 claims description 2
- 238000005406 washing Methods 0.000 claims description 2
- 238000010298 pulverizing process Methods 0.000 claims 1
- 238000007873 sieving Methods 0.000 claims 1
- 108010066551 Cholestenone 5 alpha-Reductase Proteins 0.000 abstract description 11
- 235000016709 nutrition Nutrition 0.000 abstract description 3
- 230000035764 nutrition Effects 0.000 abstract description 3
- 101000725164 Homo sapiens Cytochrome P450 1B1 Proteins 0.000 abstract description 2
- 230000003450 growing effect Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 24
- 230000000694 effects Effects 0.000 description 23
- 241000699670 Mus sp. Species 0.000 description 8
- 210000003780 hair follicle Anatomy 0.000 description 8
- 238000002835 absorbance Methods 0.000 description 7
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 229960003632 minoxidil Drugs 0.000 description 6
- 206010068168 androgenetic alopecia Diseases 0.000 description 5
- 201000002996 androgenic alopecia Diseases 0.000 description 5
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 210000004761 scalp Anatomy 0.000 description 5
- 210000003491 skin Anatomy 0.000 description 5
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- 239000006285 cell suspension Substances 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 229960004039 finasteride Drugs 0.000 description 4
- DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 210000002510 keratinocyte Anatomy 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 206010067484 Adverse reaction Diseases 0.000 description 3
- 230000006838 adverse reaction Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 230000003658 preventing hair loss Effects 0.000 description 3
- 238000003757 reverse transcription PCR Methods 0.000 description 3
- 229940074067 terminalia chebula fruit extract Drugs 0.000 description 3
- 229910021642 ultra pure water Inorganic materials 0.000 description 3
- 239000012498 ultrapure water Substances 0.000 description 3
- 208000001840 Dandruff Diseases 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 206010067482 No adverse event Diseases 0.000 description 2
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 2
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 108010087230 Sincalide Proteins 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 208000004631 alopecia areata Diseases 0.000 description 2
- 229960003473 androstanolone Drugs 0.000 description 2
- 239000007640 basal medium Substances 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 238000010609 cell counting kit-8 assay Methods 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 239000012154 double-distilled water Substances 0.000 description 2
- 230000009583 hair follicle growth Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000010413 mother solution Substances 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 1
- 206010006312 Breast swelling Diseases 0.000 description 1
- 206010006313 Breast tenderness Diseases 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 208000004547 Hallucinations Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010029240 Neuritis Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 235000014443 Pyrus communis Nutrition 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 206010042682 Swelling face Diseases 0.000 description 1
- 235000009330 Terminalia Nutrition 0.000 description 1
- 241001534869 Terminalia Species 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 208000012886 Vertigo Diseases 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 102000001307 androgen receptors Human genes 0.000 description 1
- 108010080146 androgen receptors Proteins 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000012045 crude solution Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000011841 epidemiological investigation Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000003661 hair follicle regeneration Effects 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 231100000566 intoxication Toxicity 0.000 description 1
- 230000035987 intoxication Effects 0.000 description 1
- 208000001875 irritant dermatitis Diseases 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 206010042772 syncope Diseases 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- WYWWVJHQDVCHKF-ITGWJZMWSA-J tetrasodium;[(2r,3r,4r,5r)-2-(6-aminopurin-9-yl)-5-[[[[(2r,3s,4r,5r)-5-(3-carbamoyl-4h-pyridin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-oxidophosphoryl]oxy-oxidophosphoryl]oxymethyl]-4-hydroxyoxolan-3-yl] phosphate Chemical compound [Na+].[Na+].[Na+].[Na+].C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP([O-])(=O)OP([O-])(=O)OC[C@@H]2[C@H]([C@@H](OP([O-])([O-])=O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 WYWWVJHQDVCHKF-ITGWJZMWSA-J 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 231100000889 vertigo Toxicity 0.000 description 1
- 239000012224 working solution Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
- A61K8/4953—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom containing pyrimidine ring derivatives, e.g. minoxidil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/02—Preparations for cleaning the hair
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
- A61K2800/782—Enzyme inhibitors; Enzyme antagonists
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/84—Products or compounds obtained by lyophilisation, freeze-drying
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Dermatology (AREA)
- Birds (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Botany (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Cosmetics (AREA)
Abstract
The invention discloses a composition containing myrobalan fruit extract, a preparation method, application and a hair care product. The composition containing the myrobalan fruit extract comprises the myrobalan fruit extract and a component A, wherein the component A is a caffeine and/or diaminopyrimidine oxide compound. The prepared myrobalan fruit extract-containing composition has an antioxidant effect, can effectively promote the secretion of ATP in cells, promote the secretion of vascular endothelial growth factor VEGF, promote the expression of BMP2, AR, Noggin, Ki67, IGF-1, CD44, ALPL or CYP1B1 genes, and inhibit the expression of 5 alpha-reductase; the problem of limitation of the dosage of caffeine, diaminopyrimidine oxide and pyrrolidinyl diaminopyrimidine oxide in the formula can be solved, the use safety is guaranteed, the nutrition required by hair can be provided in all directions, and a good hair loss preventing and hair growing effect is achieved.
Description
Technical Field
The invention particularly relates to a composition containing myrobalan fruit extract, a preparation method, application and a hair care product.
Background
Currently, Alopecia has become a global problem, wherein Androgenetic Alopecia (AGA) is also called as "seborrheic Alopecia", is one of the most common Alopecia diseases, and is mostly seen in middle-aged men, but women are also in an increasing trend. The onset of androgenetic alopecia is related to heredity and androgen dependence, and is mainly characterized by excessive overflow of scalp fat of a patient, often accompanied by symptoms of increased dandruff, greasy scalp and obvious pruritus, and is characterized by backward shift of hairline and progressive reduction of hair at the top of the head. The disease usually occurs in adolescence and gradually worsens with age, which seriously affects the quality of life. Epidemiological investigation in Europe and America shows that the incidence of diseases in 50-year-old people can reach 50%, and the incidence of diseases in Chinese men also reaches 21.3%. The two methods currently approved by the FDA for treating androgenetic alopecia are oral finasteride and topical minoxidil solutions, which rely primarily on inhibition of 5 α -reductase activity and inhibition of androgen receptor expression for treatment.
Oral finasteride can specifically inhibit II type 5 alpha-reductase, and reduce the generation of dihydrotestosterone in hair follicle, thereby achieving the treatment effect. However, systemic administration may have adverse reactions such as decreased libido, rash, breast tenderness or swelling, and the like, and the drug is not effective in about 30% of patients. The result of a prostate cancer prevention test of up to 7 years shows that the incidence of highly differentiated prostate cancer in finasteride group is increased compared with placebo group, which undoubtedly re-arouses the importance of finasteride safety.
Minoxidil is a vasodilator for local use for a long time, and can stimulate hair growth of patients with male hormone-induced alopecia and alopecia areata, and is suitable for treating male hormone-induced alopecia and alopecia areata. Clinically, it is occasionally reported that the use of this product may cause adverse reactions including irritant dermatitis (red swelling, dandruff and burning pain), nonspecific allergic reactions, wheal, allergic rhinitis, facial swelling, allergy, shortness of breath, headache, neuritis, vertigo, syncope, edema, chest pain, blood pressure change, palpitation and hallucination of pulse frequency, but the causal relationship between these adverse reactions and the use of minoxidil is still unclear. Topical minoxidil also has the side effect of local scalp irritation, resulting in mild dermatitis of the scalp. On the other hand, minoxidil is only used in medicine and is a prohibited material for personal care products.
Myrobalan from the region of panhimalaya is a dried ripe fruit of myrobalan (terminada chebula Retz.) and its variant terminalia chebula (var. tomentolla Kurt.) belonging to the genus terminalia of the family quisqualaceae, named chebula, chebula pear.
Caffeine has many efficacies, and thus, it is used in many kinds of cosmetics. Caffeine has therapeutic effect on alopecia of male hormone-induced alopecia patients, and is mainly achieved by the action mechanism of anti-dihydrotestosterone induced hair follicle microminiaturization. Caffeine inhibits phosphodiesterase, and stimulates cellular metabolism by up-regulating cellular cAMP levels, thereby promoting cellular proliferation. However, the mechanism for promoting hair growth is very complicated, and the application and effect are limited by simply inhibiting phosphodiesterase. In addition, in the case of long-term ingestion, a large dose of caffeine is a drug, and can cause "caffeine intoxication", so that the concentration and purity of caffeine in the formulation are also limited.
Diaminopyrimidine oxides and pyrrolidinyl diaminopyrimidine oxides, similar in structure to minoxidil, are effective antidepressants. Diaminopyrimidine oxide helps to soften collagen and can be used to treat alopecia due to premature loss of hair roots. The pyrrolidinyl diaminopyrimidine oxide provides nutrients necessary for hair roots by improving blood circulation on the skin surface, and achieves the effects of inhibiting hair loss and firming hair roots. However, the amounts of the above two components are clearly defined and limited, and the upper limit of the usage amount of diaminopyrimidine oxide for hair loss prevention and hair solidification is 1.5%. In the case of a small amount of the compound, the alopecia-preventing effect of the diaminopyrimidine oxide and the pyrrolidinyl diaminopyrimidine oxide is remarkably deteriorated.
Therefore, there is a need in the art to develop a safe and effective hair care product that can strengthen hair roots and prevent hair loss.
Disclosure of Invention
The invention aims to solve the technical problem that the existing medicine cannot give consideration to safety and effectiveness when used for treating alopecia, and provides a composition containing myrobalan fruit extract, a preparation method and application thereof, and a hair care product. The myrobalan fruit extract and the composition containing the myrobalan fruit extract have good oxidation resistance, can provide nutrition required by hair and hair follicle growth in many aspects, and effectively firms hair roots and prevents alopecia.
The invention provides a composition containing a myrobalan fruit extract, which comprises the myrobalan fruit extract and a component A, wherein the component A is a caffeine and/or diaminopyrimidine oxide compound.
The preparation method of the myrobalan fruit extract comprises the following steps: extracting dried fructus Chebulae with solvent, filtering, and drying the filtrate.
The dried myrobalan fruit may be conventional in the art, preferably dried ripe fruit of myrobalan (terminada chebula Retz.) and/or myrobalan villosa (terminada chebula Retz. var. tomentolla Kurt.) belonging to the family quisetaceae, genus myrobalan.
The dried myrobalan fruit is preferably produced from pan-himalayan belt.
The solvent may be deionized water.
The mass ratio of the dry myrobalan fruit to the solvent can be 1:8-1:11, and preferably 1: 10.
The extraction may be a conventional operation in the art, preferably a stirred extraction.
The number of times of extraction may be 1 to 3 times, preferably 2 times.
The extraction time can be 1-3h, preferably 2 h.
The temperature of the extraction may be 80-110 deg.C, preferably 90 deg.C.
The extraction preferably further comprises the steps of washing and crushing.
The comminution may be a conventional operation in the art, preferably by a high speed mill.
The crushed material may be sieved with a sieve, preferably 60 mesh.
The filtration may be a routine operation in the art, preferably centrifugation.
The drying may be carried out as is conventional in the art, preferably by freeze-drying.
The diaminopyrimidine oxide-based compound may be a diaminopyrimidine oxide and/or a pyrrolidinyl diaminopyrimidine oxide.
The composition containing fructus Chebulae extract can be used in an amount of 0.001-2%, preferably 0.003-2%.
The content of fructus Chebulae extract is 0.0001-1%, preferably 0.001-1%.
The amount of said component A may be 0.0001 to 3%, preferably 0.001 to 1.5%, more preferably 0.001 to 1.49%.
Preferably, when the component A is caffeine, the composition containing the myrobalan fruit extract is used in an amount of 0.001-2%; wherein the dosage of the myrobalan fruit extract is 0.0001-1%, and the dosage of the caffeine is 0.0001-1.49%; the mass ratio of the myrobalan fruit extract to the caffeine is 1: 15-10: 1.
Preferably, when the component A is diaminopyrimidine oxide, the myrobalan fruit extract-containing composition is used in an amount of 0.001-2%; wherein the dosage of the myrobalan fruit extract is 0.0001-1%, and the dosage of the diaminopyrimidine oxide is 0.0001-1.49%; the mass ratio of the myrobalan fruit extract to the diaminopyrimidine oxide is 1 (1-15).
Preferably, when the component A is caffeine and diaminopyrimidine oxide, the myrobalan fruit extract-containing composition is used in an amount of 0.003-2%; wherein the dosage of the myrobalan fruit extract is 0.001-1%, the dosage of the caffeine is 0.001-1.5%, and the dosage of the diaminopyrimidine oxide is 0.0001-1.5%; the mass ratio of the myrobalan fruit extract to the caffeine to the diaminopyrimidine oxide is 10 (1-10) to 1-100.
The invention also provides a preparation method of the composition containing the myrobalan fruit extract, which comprises the following steps: mixing the myrobalan fruit extract and the component A.
The invention also provides application of the composition containing the myrobalan fruit extract in preparing an anti-irritant, an antioxidant, a vascular endothelial growth factor VEGF secretion promoter, a 5 alpha-reductase inhibitor, an intracellular ATP secretion promoter or an expression promoter of a hair loss and hair growth related gene; the hair loss and hair growth related gene comprises related genes in human hair follicle dermal papilla cells, such as BMP2, AR, Noggin, Ki67, IGF-1, CD44, ALPL or CYP1B 1.
The invention also provides a hair care product which comprises the composition containing the myrobalan fruit extract.
The amount of the composition containing Terminalia chebula fruit extract in the hair care product may be 0.001-2%.
The hair care product can be a hair loss prevention product and/or a hair growth and development product.
On the basis of the common knowledge in the field, the above preferred conditions can be combined randomly to obtain the preferred embodiments of the invention.
The reagents and starting materials used in the present invention are commercially available.
The positive progress effects of the invention are as follows:
(1) the composition containing the myrobalan fruit extract can provide nutrient substances required by hair, promote the proliferation of human hair follicle papilla cells, recover the vitality of hair follicles and prevent alopecia; can improve blood circulation on scalp skin surface, and has antiinflammatory and antioxidant effects, thereby achieving effects of strengthening hair root and inhibiting hair loss;
(2) the prepared composition containing the myrobalan fruit extract has an anti-oxidation effect, can effectively promote the secretion of ATP in cells, promote the secretion of vascular endothelial growth factor VEGF, promote the expression of BMP2, AR, Noggin, Ki67, IGF-1, CD44, ALPL and CYP1B1 genes, and inhibit the expression of 5 alpha-reductase;
(3) the myrobalan fruit extract-containing composition prepared by the invention can effectively solve the problem of dosage limitation of caffeine, diaminopyrimidine oxide and pyrrolidinyl diaminopyrimidine oxide in a formula by adding the myrobalan fruit extract, can still provide nutrition required by hair in an all-around manner while ensuring safe use, and achieves good hair loss prevention and hair growth effects.
Detailed Description
The invention is further illustrated by the following examples, which are not intended to limit the scope of the invention. The experimental methods without specifying specific conditions in the following examples were selected according to the conventional methods and conditions, or according to the commercial instructions.
Example 1
100g of dried myrobalan fruits produced in the Pan-Himalayan zone are taken, cleaned, dried, crushed by a high-speed crusher and sieved by a 60-mesh sieve, 50g of powder is weighed in a round-bottom flask, 500mL of deionized water is added according to the solid-liquid ratio of 1:10, stirred and extracted, the extraction temperature is 90 ℃, and the extraction time is 2 hours. Centrifuging, filtering and collecting filtrate, adding 500mL of deionized water into filter residue, stirring and extracting for 2h at 90 ℃, centrifuging, filtering and collecting filtrate. Mixing the two filtrates, and freeze drying the filtrate to obtain fructus Chebulae extract.
Compounding the myrobalan fruit extract, caffeine and diaminopyrimidine oxide according to the mass ratio of 10:1:1 to obtain the composition containing the myrobalan fruit extract.
Effect example 1
Cytotoxicity of composition containing fructus Chebulae extract on human hair follicle papilla cells
Human Hair Follicle Dermal Papilla Cells (Hair Follicle Dermal Papilla Cells, HFDPC-P4) were plated at a level of 5000 Cells/well into 96-well cell culture plates, supernatants were removed after 72 hours of culture, serum-free DMEM basal medium was replaced for each culture well, and the Cells were starved. After the cells are starved for 16h, sample adding treatment is carried out, and a blank control group is a DMEM basic culture medium. Cells were continued at 37 ℃ with 5% CO 2 Cultured for 48h, and then the toxic effect of the myrobalan fruit extract-containing composition prepared in example 1 on human hair follicle dermal papilla cells was determined using a CCK-8 kit.
Relative cell survival rate is absorbance value of composition group containing myrobalan fruit extract/absorbance value of blank control group x 100%.
The results show that the composition containing myrobalan fruit extract has no toxic effect on human hair follicle dermal papilla cells.
Effect example 2
Cytotoxicity of composition containing fructus Chebulae extract on human keratinocyte
Recovering human keratinocyte HaCaT, placing at 37 deg.C and 5% CO 2 Culturing under the conditions of (1). Selecting cells in logarithmic growth phase at 2 × 10 4 The density of each well is inoculated on a 96-well plate, a control group and a composition experimental group containing the myrobalan fruit extract are arranged, and sample loading treatment is carried out. Cells were continued at 37 ℃ with 5% CO 2 The composition containing myrobalan fruit extract prepared in example 1 was then tested for its toxic effect on human keratinocytes using the CCK-8 kit after 24h of culture.
Relative cell survival rate-absorbance value of composition group/control group containing myrobalan fruit extract x 100%.
The results show that the composition containing myrobalan fruit extract has no toxic effect on human keratinocytes.
Effect example 3
Evaluation of Hair growth characteristics
The composition containing the myrobalan fruit extract prepared in example 1 is dissolved in ultrapure water to prepare a mother solution, and the mother solution is diluted by ultrapure water during experiment to respectively prepare the composition samples containing the myrobalan fruit extract with different concentrations for later use.
The effect of the myrobalan fruit extract-containing composition on in vivo hair follicle growth in mice was tested by applying it to the back skin. The mice were divided into 3 groups, experimental (numbered experimental 1, experimental 2) and control, each group containing 3 mice. After shaving the mice, the backs of the experimental mice were coated with a sample of a composition containing myrobalan fruit extract for seven consecutive days, and the control group was coated with ultrapure water. After each drug application, the mice were photographed, compared for the difference in skin color on the back, and observed for staining of the sections, which were performed 2 times.
The results show that the skin on the back of the mice in the experimental group becomes black and the hair growth is obviously faster than that of the control group after the composition containing the myrobalan fruit extract is smeared for seven days, and the composition containing the myrobalan fruit extract has a certain effect of promoting the hair growth of the mice.
Effect example 4
5 alpha-reductase inhibition assay
The myrobalan fruit extract-containing composition prepared in example 1 was dissolved in double distilled water to obtain solutions of different mass concentrations. Fresh 5 alpha reductase was obtained and dispensed, and stored at-80 ℃ for future use, and the protein concentration was determined by BCA method (protein quantitation). Adding reagent, phosphate buffer solution, 5 alpha reductase crude solution, anhydrous alcohol, composition containing fructus Chebulae fruit extract, testosterone and NADPH tetrasodium bicarbonate in sequence. After incubation at 37 ℃ for 10min, absorbance was measured at 340nm and the inhibitory effect of the myrobalan fruit extract-containing composition on 5 α reductase was compared.
5 alpha reductase inhibition (%) calculation formula: 5 α -reductase inhibition (%) × (absorbance value of solution added with composition containing myrobalan fruit extract/absorbance value of solution without addition of sample-1) × 100%.
The results show that the myrobalan fruit extract-containing composition is more outstanding in the capability of resisting 5 alpha reductase, and the inhibition rate is higher along with the increase of the concentration.
Effect example 5
Effect of a composition comprising Terminalia chebula fruit extract on the expression of genes associated with hair follicle papilla cells
Will be described in example 1The obtained composition containing fructus Chebulae extract is dissolved in double distilled water to obtain culture medium with different mass concentrations. Human Hair Follicle Dermal Papilla Cells (Hair Follicle Dermal Papilla Cells, HFDPC-P4) were digested and the media containing varying concentrations of a composition comprising Chebulae fruit extract were resuspended at 5X 10 5 cell/mL, using a pipette to take 20uL of cell suspension, vertically inoculating the cell suspension on an inverted 10cm culture dish cover, adding 15mL of PBS to the bottom of the 10cm culture dish, gently lifting the culture dish cover with cell drops, culturing for 72h, and harvesting spherical cultures to perform RT-PCR (reverse transcription-PCR) experiments to detect the gene expression condition.
The result shows that the composition containing the myrobalan fruit extract can obviously promote the expression of a human hair follicle dermal papilla cell growth marker gene BMP2, an androgenetic alopecia related gene AR and a hair follicle regeneration promoting gene Noggin.
Effect example 6
Effect of a composition containing myrobalan fruit extract on ATP within hair follicle papilla cells:
human Hair Follicle Dermal Papilla Cells (Hair Follicle Dermal Papilla Cells, HFDPC-P4) were plated at a level of 5000 Cells/well into 96-well cell culture plates, supernatants were removed after 72 hours of culture, serum-free DMEM basal medium was replaced for each culture well, and the Cells were starved. After the cells are starved for 16h, sample adding treatment is carried out, and a blank control group is a DMEM basic culture medium. Used after culturing for 48h
The reagent measures cellular ATP content. And (3) taking out 100 mu L of culture medium, setting a standard substance hole, adding 100 mu L of working solution, carrying out a dark reaction at room temperature for 10min, reading the plate by using a chemiluminescence microplate reader, and calculating the relative ATP content in the cell.
Relative ATP content is ATP content of the composition group containing myrobalan fruit extract/ATP content of the blank control group × 100%.
The result shows that the composition containing the myrobalan fruit extract can obviously promote the ATP content in human hair follicle dermal papilla cells.
Effect example 7
Effect of myrobalan fruit extract containing composition on hair follicle papilla cell-associated gene expression:
human Hair Follicle Dermal Papilla Cells (Hair Follicle Dermal Papilla Cells, HFDPC-P4) were digested and resuspended at 5X 10 in media containing varying concentrations of Terminalia chebula fruit extract 5 cell suspension of cells/mL, 20. mu.L of cell suspension is taken by a pipette and vertically inoculated on an inverted culture dish cover of 10cm, 15mLPBS buffer solution is added to the bottom of the culture dish of 10cm, the culture dish cover with the cell drops is cultured for 72h, and the obtained spherical culture is subjected to RT-PCR experiment.
The result shows that the composition containing the myrobalan fruit extract can obviously promote the expression of a human hair follicle dermal papilla cell proliferation marker gene Ki67, a cell growth marker gene IGF-1, a cell senescence marker gene CD44, a cell characteristic gene ALPL and an anti-pollution related protein gene CYP1B 1.
Effect example 8
Total antioxidant capacity test of compositions containing myrobalan fruit extract:
the total antioxidant capacity of the composition containing the myrobalan fruit extract is detected by using a total antioxidant capacity detection kit (ABTS rapid method) (Biyunsian S0121). ABTS is oxidized into green ABTS + under the action of a proper oxidant, the generation of ABTS + is inhibited in the presence of antioxidant, and the total antioxidant capacity of the sample can be measured and calculated by measuring the absorbance of ABTS + at 414nm or 734 nm.
The result shows that the composition containing the myrobalan fruit extract has stronger antioxidant capacity.
Claims (10)
1. A composition containing fructus Chebulae extract comprises fructus Chebulae extract and component A, wherein the component A is caffeine and/or diaminopyrimidine oxide compounds.
2. The myrobalan fruit extract-containing composition of claim 1, wherein the myrobalan fruit extract is prepared by a process comprising the steps of: extracting dried fructus Chebulae with solvent, filtering, and drying the filtrate.
3. The myrobalan fruit extract-containing composition according to claim 2, wherein the dried myrobalan fruit is a dried ripe fruit of myrobalan (Terminadia chebula Retz.) and/or myrobalan villosa (Terminadia chebula Retz. var. tomentolla Kurt.) belonging to the myrobalan genus of the family quisqualaceae; preferably, the dried myrobalan fruit is produced from pan-himalayan belt;
and/or the solvent is deionized water;
and/or the mass ratio of the dried myrobalan fruit to the solvent is 1:8-1:11, preferably 1: 10.
4. The myrobalan fruit extract-containing composition according to claim 2, wherein the extraction is performed by stirring;
and/or, the number of times of extraction is 1-3, preferably 2;
and/or the extraction time is 1-3h, preferably 2 h;
and/or the temperature of the extraction is 80-110 ℃, preferably 90 ℃.
5. The myrobalan fruit extract-containing composition of claim 2, further comprising the steps of washing and pulverizing prior to said extraction;
and/or, the comminuting is effected by a high speed comminutor;
and/or, sieving the crushed materials by a sieve, wherein the sieve preferably has 60 meshes;
and/or, the filtration is centrifugation;
and/or, the drying is freeze-drying.
6. The myrobalan fruit extract-containing composition according to claim 2, wherein the diaminopyrimidine oxide compound is a diaminopyrimidine oxide and/or a pyrrolidinyl diaminopyrimidine oxide;
and/or the dosage of the composition containing the myrobalan fruit extract is 0.001-2%, preferably 0.003-2%;
and/or, the myrobalan fruit extract is used in an amount of 0.0001-1%, preferably 0.001-1%;
and/or, the component A is used in an amount of 0.0001 to 3%, preferably 0.001 to 1.5%, more preferably 0.001 to 1.49%;
preferably, when the component A is caffeine, the composition containing the myrobalan fruit extract is used in an amount of 0.001-2%; wherein the dosage of the myrobalan fruit extract is 0.0001-1%, and the dosage of the caffeine is 0.0001-1.49%; the mass ratio of the myrobalan fruit extract to the caffeine is 1: 15-10: 1;
preferably, when the component A is diaminopyrimidine oxide, the myrobalan fruit extract-containing composition is used in an amount of 0.001-2%; wherein the dosage of the myrobalan fruit extract is 0.0001-1%, and the dosage of the diaminopyrimidine oxide is 0.0001-1.49%; the mass ratio of the myrobalan fruit extract to the diaminopyrimidine oxide is 1 (1-15);
preferably, when the component A is caffeine and diaminopyrimidine oxide, the composition containing myrobalan fruit extract is used in an amount of 0.003-2%; wherein the dosage of the myrobalan fruit extract is 0.001-1%, the dosage of the caffeine is 0.001-1.5%, and the dosage of the diaminopyrimidine oxide is 0.0001-1.5%; the mass ratio of the myrobalan fruit extract to the caffeine to the diaminopyrimidine oxide is 10 (1-10) to 1-100.
7. A process for the preparation of a myrobalan fruit extract-containing composition according to any one of claims 1-6, comprising the steps of: mixing the myrobalan fruit extract and the component A.
8. Use of a myrobalan fruit extract-containing composition as defined in any one of claims 1-6 for the preparation of an anti-irritant, an antioxidant, a vascular endothelial growth factor VEGF secretion promoter, a 5 α -reductase inhibitor, an intracellular ATP secretion promoter or an expression promoter of a hair loss and hair growth related gene; the hair loss and hair growth related gene comprises related genes in human hair follicle dermal papilla cells, such as BMP2, AR, Noggin, Ki67, IGF-1, CD44, ALPL or CYP1B 1.
9. A hair care product comprising the myrobalan fruit extract-containing composition of any one of claims 1-6.
10. The hair care product of claim 9, wherein the myrobalan fruit extract-containing composition is present in the hair care product in an amount of 0.001-2%;
and/or the hair care product is an alopecia prevention product and/or a hair growth and development product.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110185513.4A CN114903924A (en) | 2021-02-10 | 2021-02-10 | Composition containing myrobalan fruit extract, preparation method, application and hair care product |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110185513.4A CN114903924A (en) | 2021-02-10 | 2021-02-10 | Composition containing myrobalan fruit extract, preparation method, application and hair care product |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114903924A true CN114903924A (en) | 2022-08-16 |
Family
ID=82761981
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110185513.4A Pending CN114903924A (en) | 2021-02-10 | 2021-02-10 | Composition containing myrobalan fruit extract, preparation method, application and hair care product |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114903924A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111228172A (en) * | 2020-01-16 | 2020-06-05 | 辉达生物医药（苏州）有限公司 | High-efficiency hair loss prevention and hair growth composition |
| CN111658683A (en) * | 2020-05-15 | 2020-09-15 | 广东药科大学 | Application of myrobalan extract in preparation of malassezia inhibitor |
-
2021
- 2021-02-10 CN CN202110185513.4A patent/CN114903924A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111228172A (en) * | 2020-01-16 | 2020-06-05 | 辉达生物医药（苏州）有限公司 | High-efficiency hair loss prevention and hair growth composition |
| CN111658683A (en) * | 2020-05-15 | 2020-09-15 | 广东药科大学 | Application of myrobalan extract in preparation of malassezia inhibitor |
Non-Patent Citations (1)
| Title |
|---|
| 陈明岭等: "《皮肤病常用中药药理及临床》", 中国科学技术出版社 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20230147028A (en) | Composition for anti-aging, anti-inflammation or skin regeneration containing Cannabis sativa stem extract as effective component | |
| CN111686039A (en) | Whitening and skin-brightening composition and preparation method thereof | |
| CN105267268B (en) | Method for preparing folium Ginseng extract and cosmetic composition containing the same as effective component | |
| CN111789787A (en) | Composition with anti-aging effect and cosmetic thereof | |
| KR102059954B1 (en) | Manufacturing method of expanded graphite | |
| CN114903924A (en) | Composition containing myrobalan fruit extract, preparation method, application and hair care product | |
| EP2620492A1 (en) | Platelet-derived growth factor-bb production promoter, and mesenchymal stem cell production promoter, stem cell stabilizer and dermis regenerator each comprising same | |
| CN107951827A (en) | A kind of anti-oxidant skin care item and preparation method containing rosemary stem cell extract | |
| CN115054557B (en) | Alopecia preventing composition and application thereof | |
| KR101480696B1 (en) | Cosmetic composition containing extracts of Adenophora triphylla var. japonica Hara, Angelica tenuissima and crude drugs | |
| KR101427573B1 (en) | Cosmetic composition for improving skin acne containing ginseng fruit extracts | |
| KR101216113B1 (en) | The solvent fractions of propolis with suitable smell for inhibiting acne and lifting wrinkles | |
| JP7082827B2 (en) | Cosmetics | |
| EP2902022A1 (en) | Vegfc production promoter | |
| CN109602666B (en) | Whitening composition containing lime fruit extract | |
| KR101970503B1 (en) | Composition containing Scutellaria baicalensis extract and vinegars for scalp or hair | |
| KR100722955B1 (en) | The herbal composition having the skin antiaging and antiwrinkling function | |
| KR102309982B1 (en) | Skin external preparation for improving atopic dermatitis comprising extract of Eriocaulon buergerianum | |
| CN108030762A (en) | Anti-oxidant rosemary stem cell extractive composition and the skin care item containing said composition | |
| JP7454203B2 (en) | Skin external preparations or internal preparations | |
| KR101415997B1 (en) | Cosmetic composition for skin whitening containing ginseng fruit extracts | |
| CN115337226B (en) | Whitening composition, cosmetic and preparation method thereof | |
| JP7454209B2 (en) | Capillary dilation inhibitor | |
| KR101427574B1 (en) | Cosmetic composition for antiinflammation containing ginseng fruit extracts | |
| CN112120984B (en) | Composition for moisturizing and brightening skin and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB02 | Change of applicant information |
Country or region after: China Address after: 201403 Shanghai City, Fengxian District Lifenglu No. 12 Applicant after: Shanghai Natural Hall Group Co.,Ltd. Address before: 201403 Shanghai City, Fengxian District Lifenglu No. 12 Applicant before: JALA Group Co. Country or region before: China |
|
| CB02 | Change of applicant information |